 |
 |
|
|
Boost your skills by attending one of PharmaVentures' popular workshops: Advanced Valuation of Pharmaceutical Strategic Alliances25-26 October In this intensive two-day Advanced Workshop in Princeton, USA, PharmaVentures will share its insights into cutting-edge approaches, methods and techniques for the valuation of pharmaceutical products, technologies, alliances and ventures. Find out more Negotiating Successful Strategic Alliances & Calculating their Financial Terms11-13 December If you're involved in negotiating multi-million dollar licensing agreements, you'll want to get the very best out of every deal. This workshop provides a coaching opportunity for experienced negotiators as well as comprehensive training towards further involvement in the negotiation process. |
||
 |
 |
 |
Market News and TrendsDuring June 2006, PharmaDeals® Agreements recorded a total of only 18 deals relating to drug delivery, 13 fewer than the previous month. Six of these deals were between established and start-up companies and five were between two start-up companies; a further two involved global companies. By far the largest number of deals, 8 in total, comprised co-development or collaborative transactions; a further 4 were licensing agreements. Drug delivery technologies represented in June's deals include a nasal ointment, nanotechnology, a skin permeation device, a pill and sustained release and local delivery formulations. Five deals, however, focused upon oral and nasal sprays, inhalers and nebulisers, which could benefit patients with respiratory conditions and diabetes. Read more... |
||
|
|
||
Featured ArticleInhalation Technologies - A Breath of Fresh AirThe approval of Exubera® (inhaled PEGylated insulin) for the treatment of diabetes highlights the vogue for, and potential for, commercial success in reformulating existing therapies for pulmonary delivery. In this article, Joanne Pearson of PharmaVentures focuses on the proprietary mechanisms utilised by specialist biotechnology companies for the pulmonary delivery of reformulated insulin. The article also profiles three speciality drug delivery companies with pulmonary delivery expertise - Nektar Therapeutics, Aradigm and Alkermes - and the partnering approach they have taken in commercialising their technologies. Read more... |
 |
||
|
|
||
 |
Company ProfilesAegis, Cognis, Respironics, Ypsomed |
||
|
|
||
Drug Delivery OpportunitiesView all our Drug Delivery Opportunities or alternatively request a password to submit your opportunity online.Featured Opportunity Mannan-Linked DNA/RNA Delivery Administrative Route - Undisclosed Indication - Infectious diseases, cancer, gene therapy Licence code - LO-0606-07 |
 |
||
|
|
||
 |
Showcase your company to over 8000 key decision makers worldwide within the pharmaceutical and biotech sectors.Pharmaceutical and biotechnology executives refer to the Drug Delivery Report (DDR) throughout the year as the main method of independently assessing drug delivery partners.
If you want to complete a deal in 2006, then advertising in the Drug Delivery Report Autumn/Winter 2006 and on drugdeliveryreport.com is a must. Contact Wayne Chivell on +44 (0) 1865 784 177 or e-mail enquiries@pharmaventures.com to find out how you can promote your company. Copy Deadline: 22nd September 2006 |
||||||||
Comprising two specialist areas - PharmaVentures Consulting and PharmaVentures Intelligence - we work with clients to drive greater value from their deals.
If you do not wish to receive DDR E-News in future, please e-mail ddr@pharmamail.biz with the words UNSUBSCRIBE as the subject.
If you do not wish to receive other e-mail communications from PharmaVentures or selected third parties, please e-mail ddr@pharmamail.biz with REMOVE as the subject.
For more details contact
Kate Atherton, Publishing Editor, PharmaVentures Ltd, Magdalen Centre, Oxford Science Park, Oxford OX4 4GA, UK. Tel: +44 (0) 1865 784 177 Fax: +44 (0) 1865 784 178 E-mail ddr@pharmamail.biz